The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Angiotensin Receptor Blockers (ARBs) Market’s Market Value Anticipated To Evolve From 2026 To 2030?
The market for angiotensin receptor blockers (ARBs) has experienced consistent growth in recent years. This market is anticipated to expand from $8.78 billion in 2025 to $9.18 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.6%. Factors contributing to this historical growth include the increasing occurrence of hypertension, greater public awareness of cardiovascular ailments, the expansion of hospital infrastructures, the introduction of new ARB compounds, and intensified research into treatments for kidney disease.
The market for angiotensin receptor blockers (ARBs) is projected to experience consistent expansion over the upcoming years. It will grow to $11.02 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. This anticipated growth during the forecast period is driven by factors such as an aging demographic, the increasing need for tailored medical treatments, innovations in drug delivery technologies, rising healthcare spending, and the proliferation of specialty clinics. Key trends expected over this period encompass customized approaches to hypertension management, an uptick in treatments for chronic kidney disease, a broader range of cardiovascular disease therapies, greater acceptance of oral ARB formulations, and an increase in prescriptions from hospitals and specialty clinics.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp
What Important Drivers Are Powering The Angiotensin Receptor Blockers (ARBs) Market Growth?
The rising occurrence of cardiovascular diseases is projected to fuel the expansion of the angiotensin receptor blockers market in the future. Cardiovascular disease (CVD) encompasses any condition impacting the heart or blood vessels, frequently associated with the accumulation of fatty deposits within arteries (atherosclerosis) and an elevated risk of blood clots. Angiotensin receptor blockers function by reducing blood pressure and enhancing the heart’s pumping efficiency through aiding in the relaxation of veins and arteries, thereby minimizing the potential for cardiovascular disease. For instance, data from January 2024, published by the American Heart Association, a US-based non-profit organization, indicated that the age-adjusted death rate attributed to cardiovascular disease climbed to 233.3 per 100,000 in 2024, representing a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the growing prevalence of cardiovascular diseases is propelling the growth of the angiotensin receptor blockers market.
What Segment Categories Are Evaluated In The Angiotensin Receptor Blockers (ARBs) Market Study?
The angiotensin receptor blockers (arbs) market covered in this report is segmented –
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
What Trends Are Affecting The Angiotensin Receptor Blockers (ARBs) Market Dynamics?
Leading companies in the angiotensin receptor blocker market are innovating through the creation of advanced products, such as angiotensin receptor neprilysin inhibitors, to broaden treatment possibilities and enhance results for individuals with cardiovascular conditions. Angiotensin receptor neprilysin inhibitors (ARNIs) constitute a class of pharmaceuticals prescribed for managing heart failure. For example, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical firm, introduced sacubitril + valsartan tablets. These tablets are specifically formulated for the treatment of heart failure, with a focus on heart failure with reduced ejection fraction (HFrEF), and are classified as ARNI (angiotensin receptor neprilysin inhibitors). Sacubitril operates by augmenting the natriuretic peptide (NP) system, which aids in reducing fluid retention and promoting the dilation of blood vessels, while valsartan functions by inhibiting the renin-angiotensin system (RAS) to reduce blood pressure and lessen the strain on the heart. Together, they effectively alleviate symptoms of heart failure, decrease the risk of cardiovascular mortality, and reduce the probability of hospital admission due to heart failure. These medications are marketed under the brand name Sacu V.
Which Firms Are Competing In The Angiotensin Receptor Blockers (ARBs) Market?
Major companies operating in the angiotensin receptor blockers (arbs) market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma, Thermo Fisher Scientific.
Access The Complete Angiotensin Receptor Blockers (ARBs) Market Report:
Which Geographic Region Represents The Largest Angiotensin Receptor Blockers (ARBs) Market Share?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2025. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Angiotensin Receptor Blockers (ARBs) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp
Browse Through More Reports Similar to the Global Angiotensin Receptor Blockers (ARBs) Market 2026, By The Business Research Company
Angiotensin Receptor Blockers Arbs Market Report 2026
Anti Hypertensive Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model